Immunotherapy for multidrug-resistant tuberculosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores the use of Vγ2Vδ2 T lymphocyte-based immunotherapy combined with standard anti-tuberculosis chemotherapy to treat multidrug-resistant tuberculosis (MDR-TB). It aims to enhance the immune response against Mycobacterium tuberculosis, particularly in patients who have shown poor efficacy with existing treatment regimens. The approach involves administering a combination of zoledronic acid and interleukin-2 to amplify specific immune cells that can target drug-resistant TB. By integrating immunotherapy with conventional treatment, the study seeks to improve outcomes for patients with challenging MDR-TB cases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
* Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.

Exclusion Criteria:

* Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
* Test confirms poor response to ZOL and IL-2 stimulation.

Where it's running

• Shanghai Pulmonary Hospital, Shanghai, China
  Shanghai, China Recruiting
• Shanghai Pulmonary Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Sha Wei
• Email: 13671758200@126.com
• Phone: +8602165115006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Short-course radiotherapy followed by PD-1 inhibitor and FOLFOX vs standard chemoradiotherapy for high‑risk locally advanced lower rectal cancer

  This trial tests whether giving a short course of radiotherapy followed by a PD-1 inhibitor and FOLFOX can be better than the usual long-course chemoradiotherapy for adults with high‑risk, locally advanced, pMMR/MSS lower rectal cancer.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou · NCT07669220

• Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

  This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07668037

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.